Key Decisions and Financial Results

The Board meeting commenced at 02:33 PM and concluded at 03:41 PM IST, during which the following items were approved:

1. Unaudited Financial Results for Q1 FY27: Approved standalone and consolidated unaudited financial results for quarter ended June 30, 2026, reviewed by statutory auditors M/s. M S K A & Associates LLP (FRN: 105047W/W101187).

Standalone Financial Highlights (INR in millions):

  • Revenue from operations: ₹1,763.08 (vs. ₹1,307.22 in Q1 FY26)
  • Other income: ₹133.30
  • Total income: ₹1,896.38
  • Total expenses: ₹1,515.53
  • Profit before tax: ₹380.85
  • Tax expense: ₹99.17
  • Profit for the period: ₹281.68
  • EPS: ₹2.92 (basic and diluted)
  • Paid-up equity share capital: ₹963.54 million (96.354 million shares of ₹10 face value)

Consolidated Financial Highlights (INR in millions):

  • Revenue from operations: ₹3,926.54
  • Other income: ₹43.53
  • Total income: ₹3,970.07
  • Total expenses: ₹3,358.02
  • Profit before tax: ₹612.05
  • Tax expense: ₹157.82
  • Profit after tax: ₹454.23
  • Profit attributable to owners: ₹470.61
  • EPS: ₹4.88 (basic and diluted)

2. Interim Dividend Declaration: Approved first interim dividend of ₹0.50 per equity share (5% of face value ₹10) for FY 2026-27, amounting to ₹4,81,77,178.50 (approximately ₹48.18 million).

3. Record Date: Fixed Friday, August 14, 2026 as record date for determining entitlement to interim dividend.

4. ESOP Scheme 2026: Approved 'Yatharth Hospital & Trauma Care Services Employees Stock Option Scheme - 2026' covering 250,000 equity shares, subject to shareholder approval. Scheme details:

  • Exercise price not lower than face value
  • Vesting period not less than 1 year from grant
  • Exercise period not more than 2 years from vesting
  • Eligibility based on grade, service length, performance, merit, and future potential
  • Administration by Board/Nomination & Remuneration Committee

5. Cost Auditor Re-appointment: Re-appointed M/s Subodh Kumar & Co. (FRN: 104250) as cost auditor for FY 2026-27.

Operational and Strategic Updates

  • The company operates in single business segment 'Medical and Healthcare Services' and single geographical segment India.
  • During current quarter, the Group acquired an under-construction hospital in Gurugram for ₹1,000 million with capacity of 250 beds, expected to start commercial operations within next twelve months.

Legal and Regulatory Matters

  • Income Tax Department conducted searches in October 2023 under section 132 of Income Tax Act at company, subsidiary, and KMP premises.
  • Department issued provisional attachment orders under Section 281B which were subsequently released during previous year.
  • Assessment Orders issued for AY 2014-15 and 2023-24 to Holding Company and some subsidiaries.
  • Company has filed appeal against the orders and believes no material liability is expected based on internal assessment. No provision made in financial statements.

Subsidiary Information

Consolidated results include following subsidiaries:

1. AKS Medical & Research Centre Private Limited (Wholly owned)

2. Ramraja Multispeciality Hospital & Trauma Centre Private Limited (Wholly owned)

3. Sanskar Medica India Limited (Wholly owned)

4. Pristine Infracon Private Limited (Wholly owned)

5. Shantived Institute of Medical Sciences Private Limited (Wholly owned)

6. MGS Infotech Private Limited (Subsidiary)

Five subsidiaries with total revenues of ₹1,165.03 million and net profit of ₹35.98 million were reviewed by other auditors.

Additional Information

  • Previous period figures regrouped/reclassified for comparability
  • Q4 FY26 figures represent balancing figures between audited annual and unaudited quarterly figures